519 related articles for article (PubMed ID: 31574376)
1. Inhibition of autophagy enhances the anticancer effect of enzalutamide on bladder cancer.
Quan Y; Lei H; Wahafu W; Liu Y; Ping H; Zhang X
Biomed Pharmacother; 2019 Dec; 120():109490. PubMed ID: 31574376
[TBL] [Abstract][Full Text] [Related]
2. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H
Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033
[TBL] [Abstract][Full Text] [Related]
3. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
[TBL] [Abstract][Full Text] [Related]
4. Concurrent Autophagy Inhibition Overcomes the Resistance of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Human Bladder Cancer Cells.
Kang M; Lee KH; Lee HS; Jeong CW; Kwak C; Kim HH; Ku JH
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28165387
[TBL] [Abstract][Full Text] [Related]
5. Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder.
Tyagi A; Chandrasekaran B; Kolluru V; Rai S; Jordan AC; Houda A; Messer J; Ankem M; Damodaran C; Haddad A
Urol Oncol; 2019 Jul; 37(7):492-502. PubMed ID: 31006613
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
Shiota M; Bishop JL; Takeuchi A; Nip KM; Cordonnier T; Beraldi E; Kuruma H; Gleave ME; Zoubeidi A
Oncotarget; 2015 Apr; 6(11):9086-98. PubMed ID: 25871401
[TBL] [Abstract][Full Text] [Related]
8. Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.
Toren P; Kim S; Cordonnier T; Crafter C; Davies BR; Fazli L; Gleave ME; Zoubeidi A
Eur Urol; 2015 Jun; 67(6):986-990. PubMed ID: 25151012
[TBL] [Abstract][Full Text] [Related]
9. Autophagy induction enhances tetrandrine-induced apoptosis via the AMPK/mTOR pathway in human bladder cancer cells.
Kou B; Liu W; Xu X; Yang Y; Yi Q; Guo F; Li J; Zhou J; Kou Q
Oncol Rep; 2017 Nov; 38(5):3137-3143. PubMed ID: 29048631
[TBL] [Abstract][Full Text] [Related]
10. Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells.
Lin JF; Lin YC; Yang SC; Tsai TF; Chen HE; Chou KY; Hwang TI
Drug Des Devel Ther; 2016; 10():1501-13. PubMed ID: 27143856
[TBL] [Abstract][Full Text] [Related]
11. Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth.
Zhang M; Sun Y; Meng J; Zhang L; Liang C; Chang C
Cancer Lett; 2019 Feb; 442():483-490. PubMed ID: 30423407
[TBL] [Abstract][Full Text] [Related]
12. BET inhibitor JQ1 suppresses cell proliferation via inducing autophagy and activating LKB1/AMPK in bladder cancer cells.
Li F; Yang C; Zhang HB; Ma J; Jia J; Tang X; Zeng J; Chong T; Wang X; He D; Guo P
Cancer Med; 2019 Aug; 8(10):4792-4805. PubMed ID: 31250978
[TBL] [Abstract][Full Text] [Related]
13. Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression.
Chen J; Li L; Yang Z; Luo J; Yeh S; Chang C
Cancer Lett; 2017 Nov; 408():155-163. PubMed ID: 28826721
[TBL] [Abstract][Full Text] [Related]
14. Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
Wu H; Zhang L; Gao X; Zhang X; Duan J; You L; Cheng Y; Bian J; Zhu Q; Yang Y
Cancer Lett; 2017 Jan; 385():108-116. PubMed ID: 27815035
[TBL] [Abstract][Full Text] [Related]
15. Enzalutamide inhibits proliferation of gemcitabine-resistant bladder cancer cells with increased androgen receptor expression.
Kameyama K; Horie K; Mizutani K; Kato T; Fujita Y; Kawakami K; Kojima T; Miyazaki T; Deguchi T; Ito M
Int J Oncol; 2017 Jan; 50(1):75-84. PubMed ID: 27909718
[TBL] [Abstract][Full Text] [Related]
16. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
Wang R; Lin W; Lin C; Li L; Sun Y; Chang C
Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475
[TBL] [Abstract][Full Text] [Related]
17. Chloroquine Enhances the Radiosensitivity of Bladder Cancer Cells by Inhibiting Autophagy and Activating Apoptosis.
Wang F; Tang J; Li P; Si S; Yu H; Yang X; Tao J; Lv Q; Gu M; Yang H; Wang Z
Cell Physiol Biochem; 2018; 45(1):54-66. PubMed ID: 29316551
[TBL] [Abstract][Full Text] [Related]
18. siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.
Yamamoto Y; Lin PJ; Beraldi E; Zhang F; Kawai Y; Leong J; Katsumi H; Fazli L; Fraser R; Cullis PR; Gleave M
Clin Cancer Res; 2015 Nov; 21(21):4845-55. PubMed ID: 26106075
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin induces protective autophagy through activation of BECN1 in human bladder cancer cells.
Lin JF; Lin YC; Tsai TF; Chen HE; Chou KY; Hwang TI
Drug Des Devel Ther; 2017; 11():1517-1533. PubMed ID: 28553083
[TBL] [Abstract][Full Text] [Related]
20. Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer.
Thaper D; Vahid S; Kaur R; Kumar S; Nouruzi S; Bishop JL; Johansson M; Zoubeidi A
Sci Rep; 2018 Nov; 8(1):17307. PubMed ID: 30470788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
